OXON Epidemiology is a European based full-service Contract Research Organisation (CRO) specialising in primary & secondary data collection and hybrid observational studies for safety, market access and drug development in all major therapeutic areas, including orphan drugs. • Multi-country field, chart review and database epidemiological studies • Patient registries • Risk management, PASS and Risk minimisation studies • Statistical signal detection & analysis • Quantitative benefit-risk analysis for CTD / PBRER • Patient reported outcomes • Health economics & modelling • Meta-analysis and Evidence Synthesis We have an experienced team and a international network of clinical and world-renowned academic consultants, being among OXON staff publications: Lancet (x8), JAMA (x1) and BMJ (x3). OXON epidemiology is a partner centre of ENCePP (European Network of Centres in Pharmacoepidemiology and Pharmacovigilance), which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the EU PAS Register, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies OXON strives to be the Go-To leader in the design and implementation of outstanding observational studies. Our mission is to integrate methodological and statistical thinking and insights to maximize value and provide solutions for our clients. Combining quality science and operational experience we help large and small biopharmaceutical and medical devices companies worldwide obtain high-quality RWE for Safety, Market Access, and Clinical Development for improving patient’s care and public health.
